Anabelle Terry, a slender, self-possessed 13-year-old, has heard the peanut butter story her entire life. A visit to an ...

Dupilumab may provide a nonsteroidal option for managing cancer therapy-related skin toxicities, according to a study.

Regeneron Pharmaceuticals and Sanofi are collaborating on a Phase 4 clinical study titled ‘A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Dupilumab on Airway ...

The broader Sanofi and Regeneron COPD clinical research program includes Phase 3 trials with itepekimab, a fully human monoclonal antibody that binds to and inhibits interleukin-33 (IL-33).

Patients with chronic rhinosinusitis with nasal polyps show high treatment persistence with dupilumab, with a substantial proportion restarting therapy after discontinuation.

News provided by Regeneron Pharmaceuticals, Inc. Feb 16, 2024, 12:59 AM ET Approval based on results from Phase 3 trial showing Dupixent significantly reduced itch compared to placebo CSU is the ...

To date, dupilumab has been studied across more than 60 clinical trials involving more than 10,000 patients with various chronic diseases driven in part by type 2 inflammation.